Underwriting AgreementKiniksa Pharmaceuticals, Ltd. • May 18th, 2020 • Pharmaceutical preparations • New York
Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,400,000 Class A common shares (the “Firm Shares”) and, at the election of the Underwriters, up to 360,000 additional Class A common shares (the “Optional Shares”) of the Company (such Class A common shares of the Company being referred to herein as the “Common Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares.”
